ACXP (Acurx Pharmaceuticals, Inc.) Short-Term Debt to Capital

Acurx Pharmaceuticals (ACXP) is scaling innovative drugs to combat dangerous intestinal infections as it prepares for final FDA testing. The business leverages global medical priorities, ensuring its success remains independent of market cycles. The company's price evolution, where the indicator stands at 0.00, confirms the value of its clinical partnerships, significantly enhancing the startup's investment appeal for potential buyers.

This ratio determines the share of liabilities with a maturity of over one year within the equity structure, while the current level of short-term capital load stands at 0.00, allowing for an assessment of the financial stability of Acurx Pharmaceuticals (ACXP) during the implementation of robotic molecule design systems and laboratory test automation to accelerate the discovery of new antibiotics.